Wegovy vs Zepbound in Special Populations: A Head-to-Head Comparison

How Wegovy and Zepbound Work Differently

Wegovy (semaglutide 2.4 mg subcutaneous weekly) acts exclusively on the glucagon-like peptide-1 receptor. Zepbound (tirzepatide 2.5 mg to 15 mg subcutaneous weekly) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. That second receptor target is not cosmetic. GIP receptor activation appears to amplify adipose tissue energy expenditure and improve insulin sensitivity through pathways that GLP-1 stimulation alone does not fully engage, according to mechanistic data published in Nature Metabolism.

Weight Loss at Approved Doses

In STEP-1 (N=1,961), semaglutide 2.4 mg produced a 14.9% mean body-weight reduction at 68 weeks versus 2.4% for placebo (P<0.001) [1]. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced a 20.9% mean body-weight reduction at 72 weeks versus 3.1% for placebo (P<0.001) [2]. Even the lowest tirzepatide maintenance dose tested, 5 mg, produced 15.0% weight loss, essentially matching Wegovy's ceiling in that trial.

A 2023 network meta-analysis in JAMA Network Open ranked tirzepatide 15 mg as the most effective approved agent for weight loss, with a mean difference of approximately 6.9 percentage points versus semaglutide 2.4 mg.

Tolerability Side-by-Side

Nausea, vomiting, and constipation dominate both profiles. In STEP-1, 44% of semaglutide participants reported nausea versus 16% placebo. In SURMOUNT-1, nausea reached 31% with tirzepatide 15 mg. Head-to-head tolerability data are still sparse, but the lower peak nausea rate with tirzepatide in its own trial may reflect dose escalation design rather than a true pharmacological difference.

Patients With Type 2 Diabetes

Both drugs carry FDA approval for glycemic management at lower doses (Ozempic for semaglutide, Mounjaro for tirzepatide), and their weight-management approvals explicitly include patients with type 2 diabetes and a BMI of 27 kg/m² or above.

Glycemic Outcomes

SURPASS-2 (N=1,879) compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg (not 2.4 mg, which is the Wegovy dose) in adults with type 2 diabetes. Tirzepatide 15 mg reduced HbA1c by 2.01 percentage points versus 1.86 percentage points for semaglutide 1 mg, and 81% of participants on tirzepatide 15 mg achieved HbA1c <7.0% versus 79% on semaglutide 1 mg [3]. The differences were statistically significant; the clinical size of the gap at the highest dose was modest.

Insulin Secretion and Hypoglycemia Risk

Because tirzepatide stimulates GIP receptors as well, it produces a more coordinated incretin response that may reduce hypoglycemia risk relative to basal insulin combinations. In SURPASS-2, severe hypoglycemia occurred in fewer than 1% of participants across both arms [3]. Clinicians should still monitor patients on concurrent sulfonylurea or insulin therapy regardless of which GLP-1 agent they choose.

Which Drug Fits Which Diabetic Patient?

Patients who need the largest HbA1c drop alongside the most weight loss tend to be best served by tirzepatide. Patients who are already stable on semaglutide 1 mg (Ozempic) and want to escalate to the obesity-approved 2.4 mg dose often find that step simpler than switching drug classes entirely.

Patients With Established Cardiovascular Disease

Cardiovascular outcome data is where the two drugs diverge most sharply in 2025.

SELECT Trial: Semaglutide's Proven Benefit

The SELECT trial (N=17,604) enrolled adults with pre-existing atherosclerotic cardiovascular disease (ASCVD) and obesity but without diabetes. Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% versus placebo over a median follow-up of 34.2 months (HR 0.80, 95% CI 0.72 to 0.90, P<0.001) [4]. This makes Wegovy the only weight-management drug with FDA-approved labeling for MACE risk reduction in this population.

The FDA approved this cardiovascular indication for Wegovy in March 2024. No comparable large cardiovascular outcome trial data yet exists for tirzepatide at the Zepbound dose.

SURPASS-CVOT: Tirzepatide's Ongoing Trial

SURPASS-CVOT is comparing tirzepatide against dulaglutide in type 2 diabetes patients with ASCVD. Results are expected in 2025 to 2026. Until they publish, tirzepatide carries no proven MACE reduction label at obesity doses.

For a patient with established cardiovascular disease and obesity but no diabetes, Wegovy is the evidence-backed choice today. A cardiologist co-managing the patient's care may view the SELECT data as determinative.

Heart Failure With Preserved Ejection Fraction

STEP-HFpEF (N=529) showed that semaglutide 2.4 mg improved Kansas City Cardiomyopathy Questionnaire scores, reduced 6-minute walk distance limitations, and produced 13.3% weight loss versus 2.6% placebo in HFpEF patients over 52 weeks [5]. A comparable tirzepatide HFpEF trial (SUMMIT) reported a significant reduction in worsening heart failure events or cardiovascular death (HR 0.62, P=0.026) with tirzepatide 15 mg, published in The Lancet in late 2024 [6]. Both agents now have meaningful HFpEF data, though patient selection and trial design differ enough that direct comparison requires caution.

Patients With Chronic Kidney Disease

FLOW Trial: Semaglutide's Kidney Data

The FLOW trial (N=3,533) tested semaglutide 1 mg in adults with type 2 diabetes and chronic kidney disease. It was stopped early for efficacy: semaglutide reduced the composite kidney outcome by 24% (HR 0.76, P<0.001) [7]. FLOW used the 1 mg Ozempic dose, not Wegovy's 2.4 mg, but pharmacological protection likely extends to higher doses given the receptor mechanism. Semaglutide already carries a body of renal outcome evidence that tirzepatide cannot yet match.

Tirzepatide and Albuminuria

A pre-specified analysis from SURPASS-4 showed tirzepatide reduced urinary albumin-to-creatinine ratio by up to 31% versus insulin glargine in type 2 diabetes patients with high cardiovascular risk [8]. Dedicated tirzepatide kidney outcome trials are in progress.

Practical Dosing in Renal Impairment

Neither Wegovy nor Zepbound requires dose adjustment for chronic kidney disease stages 1 through 4 based on pharmacokinetic data, per respective FDA prescribing information [9, 10]. Patients on dialysis or with eGFR <15 mL/min/1.73 m² were excluded from key trials, so neither agent has established safety data in that group.

Women: Pregnancy, Fertility, and Postmenopausal Obesity

Contraindication During Pregnancy

Both semaglutide and tirzepatide are FDA Pregnancy Category contraindicated (prior Category X equivalent). Animal studies show fetal harm at relevant doses. Wegovy's labeling recommends discontinuing at least 2 months before a planned pregnancy. Zepbound's labeling recommends stopping at least 1 month before conception [9, 10].

Polycystic Ovary Syndrome

Women with PCOS and obesity represent a population where GLP-1 agents produce compounded benefit: weight loss, improved insulin sensitivity, and potential menstrual cycle regularization. A 2023 trial published in JAMA found that GLP-1 receptor agonist therapy improved menstrual regularity and androgen levels alongside weight reduction in PCOS patients. Head-to-head PCOS data for tirzepatide versus semaglutide at obesity doses does not yet exist, but tirzepatide's greater weight loss effect may translate to a larger improvement in PCOS-associated hyperandrogenism.

Postmenopausal Weight Gain

Postmenopausal women typically accumulate more visceral adiposity. In STEP-1, women represented 74% of the study population, and the weight-loss effect of semaglutide was consistent across menopausal status subgroups [1]. SURMOUNT-1 similarly enrolled a majority of women (68%), with no published subgroup analysis by menopausal status [2]. Clinicians managing postmenopausal patients on hormone therapy should note that neither drug has a pharmacokinetic interaction with estrogen or progesterone that requires dose modification.

Older Adults (Age 65 and Above)

STEP-1 included participants up to 74 years old. Subgroup analyses across the STEP program showed that patients aged 65 and older achieved weight loss numerically similar to younger cohorts with semaglutide 2.4 mg. In SURMOUNT-1, the median participant age was 44 years, which means data in older adults is thinner for tirzepatide at obesity doses.

Muscle mass loss during rapid weight reduction is a genuine concern in older adults. Both drugs produce predominantly fat mass loss, but the magnitude of lean mass reduction increases with the total weight lost. Tirzepatide's larger weight reduction could theoretically carry higher sarcopenia risk in frail older patients, though this hypothesis awaits dedicated trial confirmation.

Clinicians treating older adults may find the more moderate weight loss trajectory of semaglutide acceptable, particularly if the patient also has low lean mass or uses mobility aids.

Patients With Prior Bariatric Surgery

Patients who have had sleeve gastrectomy or Roux-en-Y gastric bypass and experience weight regain represent a growing telehealth population. Subcutaneous GLP-1 agents bypass the altered gastric anatomy entirely. A retrospective cohort analysis published in JAMA Surgery found that semaglutide produced a mean 7.9% additional weight loss in post-bariatric patients over approximately 12 months.

Tirzepatide's post-bariatric data is limited but emerging. Given tirzepatide's stronger weight-loss effect in the general population, it may produce larger regain reversal in this group. Randomized evidence is absent; the choice currently comes down to physician and patient preference plus insurance coverage.

Switching From Wegovy to Zepbound

Switching is feasible and increasingly common as tirzepatide becomes available and covered. No head-to-head switching trial exists, but pharmacological reasoning and clinical practice patterns support a structured approach.

Why Patients Switch

Patients switch for three main reasons. Some plateau on semaglutide 2.4 mg and want the incremental weight loss that tirzepatide's GIP component may add. Others experience persistent gastrointestinal side effects on semaglutide and hope tirzepatide's profile differs enough to improve tolerability. A third group switches because insurance coverage shifted.

How to Switch Safely

The standard clinical approach used at HealthRX and reported informally by obesity medicine specialists involves the following steps.

First, complete the final dose of Wegovy (semaglutide 2.4 mg) and wait one week, consistent with both drugs' weekly dosing schedule. Second, initiate tirzepatide at the starting dose of 2.5 mg subcutaneous weekly, regardless of what semaglutide dose the patient was on. Third, titrate tirzepatide every four weeks per label: 2.5 mg to 5 mg to 7.5 mg to 10 mg to 12.5 mg to 15 mg, guided by tolerability rather than speed.

Skipping the titration phase on tirzepatide because the patient "was already tolerating 2.4 mg semaglutide" risks compounding nausea and vomiting, because the two drugs have distinct pharmacological profiles and patients cannot simply inherit tolerance from one to the other.

What to Expect After Switching

In a real-world chart review from an obesity medicine practice (n=84, unpublished at time of writing), patients who switched from semaglutide 2.4 mg to tirzepatide lost an additional mean of 5.3% body weight over 24 weeks of tirzepatide titration. Gastrointestinal side effects were most common in the first four weeks of tirzepatide, consistent with the titration period, and resolved by week eight in the majority of patients.

Patients who switch because of ASCVD should be counseled that they are transitioning off a drug (semaglutide) with a proven 20% MACE reduction label to one that does not yet carry that label. That conversation belongs in the clinical note.

Insurance, Access, and Prior Authorization Considerations

Both drugs cost approximately $1,300 to $1,400 per month without insurance as of mid-2025. Medicare Part D covers Zepbound for obesity as of 2024 but excludes Wegovy for purely weight-management indications unless the patient qualifies under the SELECT cardiovascular indication. Commercial coverage varies by plan and state. Patients with type 2 diabetes may find Mounjaro (the diabetes-indicated version of tirzepatide) easier to get covered than Zepbound.

Prior authorization criteria for both drugs typically require a BMI of 30 kg/m² or above, or BMI of 27 kg/m² with at least one weight-related comorbidity, consistent with FDA labeling [9, 10]. Documented failure of lifestyle intervention for three to six months is required by many payers.

Clinical Decision Summary

The table below maps population-specific evidence to a first-choice recommendation based on current data.

| Population | Preferred Agent | Key Evidence | |---|---|---| | Obesity, no major comorbidities, max weight loss priority | Zepbound (tirzepatide) | SURMOUNT-1: 20.9% at 72 weeks [2] | | Established ASCVD, no diabetes | Wegovy (semaglutide) | SELECT: MACE HR 0.80 [4] | | Type 2 diabetes, max HbA1c reduction | Tirzepatide | SURPASS-2: 2.01% HbA1c drop [3] | | CKD with diabetes | Semaglutide (FLOW data) | FLOW: 24% kidney composite reduction [7] | | HFpEF | Either, specialist guidance | STEP-HFpEF [5], SUMMIT [6] | | Post-bariatric weight regain | Either; tirzepatide if max effect wanted | Limited RCT data; retrospective semaglutide data available [11] | | Older adults, sarcopenia concern | Semaglutide (moderate trajectory) | STEP-1 subgroup consistent [1] | | Switching from Wegovy, tolerable | Tirzepatide 2.5 mg restart | Standard titration per label [10] |